SE9502926D0 - Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
- Google Patents
Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
Info
Publication number
SE9502926D0
SE9502926D0SE9502926ASE9502926ASE9502926D0SE 9502926 D0SE9502926 D0SE 9502926D0SE 9502926 ASE9502926 ASE 9502926ASE 9502926 ASE9502926 ASE 9502926ASE 9502926 D0SE9502926 D0SE 9502926D0
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replico Medical AbfiledCriticalReplico Medical Ab
Priority to SE9502926ApriorityCriticalpatent/SE9502926D0/sv
Publication of SE9502926D0publicationCriticalpatent/SE9502926D0/sv
SE9502926A1995-08-241995-08-24Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
SE9502926D0
(sv)
Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
Epitope specific B-cell anergy in HiV-infection: New HIV-1 peptides, diagnostic antigens to detect the anergy, their use, vaccines and medicaments to prevent and treat it
Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses